The increasing drug prices in Europe

Vytenis Andriukaitis

Vytenis Andriukaitis, Member of the EC in charge of Health and Food Safety, and Carlos Moedas, Member of the EC in charge of Research, Science and Innovation, awarded the “Horizon Prize – Better Use of Antibiotics” and “The EU Health Awards for NGO’s fighting Antimicrobial Resistance” at a ceremony hold in Leuven. © European Union , 2017 / Source: EC – Audiovisual Service / Photo: Lukasz Kobus.

This article was written by one of our passionate readers, Mrs Rachel Everly. The opinions expressed within reflect only the writer’s views and not The European Sting’s position on the issue.

Rising drug prices have not been a recent issue, it has always been a part and parcel of the medical expenses. Not only is the United States suffering through a spike in the prices of medicines, but European medical bills have taken a toll for the worse as well. Prior to that, Europe had refrained from huge raises in the prices and until 2011, the selling price of many prescription pills had been steadily low.

Since most of the European nations are funding the healthcare systems on a government level, it is only understandable that they would want to keep a close track of the pharmaceutical industry. Due to this reason, the European Pharmaceutical companies are known to work on laws and regulations that restrict them from increasing the prices of the medicines for more than once a year. The price, profits, and comparison of the prices with the international market were always screened and assessed throughout the year without adjusting the prices.

In 2011, many European countries saw a gradual rise in multiple medicines and the rates have been rising ever since, without any restriction. This will affect many consumers and the fee structure of their individual health plans. To counter this problem, European Parliament’s environment Committee (ENVI) is favoring a non-legislative proposition that will strive for making these products more widespread in the European region. However, this must not be confused with an actual law being added in the region’s policies, as it is merely a resolution waiting to be approved by the authorities. With time, it may be considered and the European Union may only then choose to implement it.

The price of specific drugs has been a matter of huge concern for the public. Looking at the prices of those medicines in the previous years has shown an increase in prices for as much as over 1000%. Drugs that are used for leukemia patients have an increased price of 1225%, while tamoxifen, which is used primarily for breast cancer has risen by 1080% from 2011 to 2016. A chemotherapy drug has seen a spike of 1500% but later was fined for 5 million euros for an illegal increase in the price.

Charges of relatively new drugs that have little to no competition are also in the race for increasing their prices up to stupendous amounts. Multiple Sclerosis and Cancer treatment drugs are hiking due to lack of competition and insurance companies and pharmacy beneficiaries are losing against keeping these companies at bay.

The setting not only destabilizes the people who are insured but deeply affects the people who chose not to be insured or cannot afford healthcare. Previously, a person who could not have afforded to have themselves operated could find comfort in medicines. The same is not the case anymore and medical prescription drugs have become even more unattainable than before for many uninsured people out there. Seniors who have retired and do not have an insurance plan can also be looking at paying higher prices than they have previously been paying.

It has been debated for more than one year that the prices of the drugs do not represent the true cost of its production. It is concluded that the price of its manufacturing is far lower than the price label put on the product.  Most of these increments in prices have more to do with profits for these drug manufacturing companies and little to do with the increasing demands and lack of supply. To counter any research and development aspect of a new drug and decrease its cost, the patient-driven research is promoted. This means that the patient can sponsor the research and have the cure developed and tested.

Another speculation that has also been made is that due to the fact that they are only allowed to raise the costs once a year. This has made the marketers overly cautious and in order to withstand any possible demand and supply problem, or a price hike in the global market, they increase their rates by a huge percentage.

In order to provide a safer and more affordable plan for the healthcare system, the government, the people, and the drug manufacturers must work together. More and more efforts have been put on by EU health ministers in 2016 to warn the pharmaceuticals to lower the prices down as it has created a market that is highly unapproachable.

Join the Hive!

the sting Milestone

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

MEPs call for safety and liability rules for driverless cars

Bosnia and Herzegovina: EU allocates additional €3.5 million to support vulnerable refugees and migrants

Half the world’s refugee children not in school, UN agency finds

2014 will bring more European Union for the big guys and less for the weak

South Eurozone urgently needs fairer distribution of taxation burden

To feed 10 billion people, we must preserve biodiversity. Here’s how

Parliament requests further action to save EU tourism

The silent code blue- a call for health worker’s safety

The United States divorce rate is dropping, thanks to millennials

Taking care in times of social isolation goes beyond washing hands or wearing masks

G20 LIVE: G20 leaders reaffirm OECD’s role in ensuring strong, sustainable and inclusive growth

‘I thought I’d never get out alive’ – the Muslim director who interviewed neo-Nazis

Over 330,000 Congolese migrants at risk after mass deportations from Angola – UN rights chief

‘Provocative actions and inflammatory rhetoric’ destabilizing Middle East, warns top UN official

Smoking VS Vaping: is it a battle?

The world’s economy is only 9% circular. We must be bolder about saving resources

Security Union: A Counter-Terrorism Agenda and stronger Europol to boost the EU’s resilience

UN chief pays tribute to the courage of DR Congo citizens, and the sacrifice of blue helmets

Hardened creditors drive Greece to dire straits; Tsipras desperate for an agreement

No great discovery was made without a bold guess – Isaac Newton

OECD Donor countries need to reform development finance to meet 2030 pledge

How trade wars pose a threat to the global economy

Austria: reforms will be necessary to uphold high well-being levels

Human Rights Council election: 5 things you need to know about it

How can the EU hit net-zero emissions?

Digital learning can help us close the global education gap. This is how

EU security and defence industry prepares positions for ‘producers’ and ‘customers’

More attacks, ‘persisting security challenges’ threaten progress in West Africa, Sahel

Youth for Climate Change

North Korea missile tests ‘deeply troubling’: senior UN official

How can we build a workforce for our digital future?

Populist Eurosceptics helped by Trumpists seriously threaten the EU edifice

Eurozone: Inflation plunge to 0.4% in July may trigger cataclysmic developments

The latest technology isn’t enough – you need the business model to go with it

Energy Union: deals on efficiency targets and governance

If we don’t protect the ocean, humanitarian disaster awaits

IMF’s Lagarde indirectly cautioned Eurozone on deflation

Trump’s Syrian hit the softest option vis-a-vis Russia

Where is Egypt leading the Middle East and the Mediterranean economy?

European Commission authorises second safe and effective vaccine against COVID-19

GradList Launched At TheNextWeb 2014

Africa-Europe Alliance: Denmark provides €10 million for sustainable development under the EU External Investment Plan

To rebuild trust in the media, we must empower its consumers

Germany and Europe prepare for Trump’s America

Eurogroup asked to reduce public debts of its member states

What’s behind South Korea’s elderly crime wave?

Medicine and mental health: relax, the doctor is a lifelong learner

Spending on health increase faster than rest of global economy, UN health agency says

Campaign kicks off with High-level Event on #FairInternships

Tackling the toxic norms that hold women back in Asia

Act now to end violence, Zeid urges Nicaraguan authorities

Efforts to save the planet must start with the Antarctic

Transport Committee pledges to stop empty flights due to COVID-19

Hiring more female leaders is good for profits. Here’s the evidence

‘Preserve, revitalize and promote’ indigenous languages, or lose a ‘wealth of traditional knowledge’, UN chief says

Europe led by Germany seems vulnerable to Trump’s threats

Labels for tyres: deal for greener and safer road transport

Pro-EU forces won a 70% triumph in the European elections

With 5 billion set to miss out on health care, UN holds landmark summit to boost coverage

Energy security: The synchronisation of the Baltic States’ electricity networks – European solidarity in action

More Stings?

Advertising

Trackbacks

  1. […] The cost of new medical technologies and drugs remains the primary cause of the high rate of medical inflation: this is why a discussion at European level with the European Federation of Pharmaceutical Industries and Associations is still open: drug pricing is at the top of the bill. […]

  2. […] Il costo di nuove tecnologie e medicinali rimane la causa principale dell’aumento dei tassi di inflazione medica: questo è il motivo per cui a livello europeo è in corso una discussione con l’Associazione Europea delle Compagnie Farmaceutiche. Il punto principale dell’agenda è sempre quello: il continuo aumento dei medicinali. […]

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s